Lupin Limited has signed an exclusive license, supply, and distribution agreement with Gan&Lee Pharmaceuticals of China for Bofanglutide, a novel fortnightly GLP-1 receptor agonist. Under the agreement, Lupin will have exclusive rights to commercialize the product in India for the treatment of type 2 diabetes and weight management in overweight and obese adults.
Bofanglutide is administered once every two weeks, offering a reduced injection frequency compared with existing weekly GLP-1 therapies. Clinical data indicate that the drug delivers weight loss and glycaemic control outcomes comparable to or better than currently available alternatives, while maintaining a safety and tolerability profile consistent with the GLP-1 class.
The agreement strengthens Lupin’s metabolic health portfolio and supports its entry into the obesity treatment segment. India faces a growing burden of metabolic diseases, with an estimated 90 million adults living with diabetes and nearly 50 million classified as obese. The convenience of a fortnightly dosing regimen may improve treatment adherence for patients requiring long-term therapy.
Commenting on the partnership, Nilesh Gupta, Managing Director of Lupin, said the agreement reflects the company’s commitment to expanding access to innovative therapies for chronic metabolic conditions. Rajeev Sibal, President – India Region Formulations, added that the reduced injection frequency provides a meaningful advantage while delivering clinically proven outcomes.
Gan&Lee Pharmaceuticals stated that the partnership aligns with its strategy to expand globally and bring its innovations to new markets. The company is a leading insulin manufacturer in China and has received regulatory approvals in multiple international markets, including GMP clearance from the European Medicines Agency.
Lupin Limited is headquartered in Mumbai and operates in over 100 markets worldwide, with a strong presence in India and the United States. The company manufactures branded and generic formulations, complex generics, biotechnology products, and APIs across 15 manufacturing sites and seven research centers globally.
